NCT02608268 2023-12-06Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesNovartisPhase 1/2 Terminated252 enrolled 67 charts
NCT03233724 2023-05-31Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal CarcinomasNational Institutes of Health Clinical Center (CC)Phase 1/2 Terminated9 enrolled 14 charts